Related Experiment Video
Updated: Aug 26, 2025
Manufacture and Drug Delivery Applications of Silk Nanoparticles
Published on: October 8, 2016
Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy
Zhengting Jiang1, Wenjie Zhang1, Jie Zhang1
1Clinical Medical College, Yangzhou University, Yangzhou, 225000, People's Republic of China.
Abstract:
Cancer immunotherapy, a major breakthrough in cancer treatment, has been successfully applied to treat a number of tumors. However, given the presence of factors in the tumor microenvironment (TME) that impede immunotherapy, only a small proportion of patients achieve a good clinical response. With the ability to increase permeability and cross biological barriers, nanomaterials have been successfully applied to deliver immunotherapeutic agents, thus realizing the anti-cancer therapeutic potential of therapeutic agents. This has driven a wave of research into systems for the delivery of immunotherapeutic agents, which has resulted in widespread interest in nanomaterial-based drug delivery systems. Nanomaterial-based drug delivery systems are able to overcome the challenges from TME and thus achieve good results in cancer immunotherapy. If it can make a breakthrough in improving biocompatibility and reducing cytotoxicity, it will be more widely used in clinical practice. Different types of nanomaterials may also have some subtle differences in enhancing cancer immunotherapy. Moreover, delivery systems made of nanomaterials loaded with drugs, such as cytotoxic drugs, cytokines, and adjuvants, could be used for cancer immunotherapy because they avoid the toxicity and side effects associated with these drugs, thereby enabling their reuse. Therefore, further insights into nanomaterial-based drug delivery systems will provide more effective treatment options for cancer patients.
Insights
Nanomaterials enhance cancer immunotherapy by overcoming the tumor microenvironment (TME). These drug delivery systems show promise for more effective cancer treatments, pending improvements in biocompatibility and reduced cytotoxicity.
Area of Science:
- Oncology
- Nanotechnology
- Immunology
Background:
- Cancer immunotherapy is a significant advancement in cancer treatment, but its efficacy is limited by the tumor microenvironment (TME).
- Only a subset of patients respond well to current immunotherapies due to TME-induced impediments.
- Nanomaterials offer a solution by enhancing drug delivery and overcoming biological barriers.
Purpose of the Study:
- To explore the role of nanomaterial-based drug delivery systems in overcoming TME challenges for improved cancer immunotherapy.
- To review the potential of nanomaterials in enhancing the delivery of immunotherapeutic agents.
- To discuss the future prospects and challenges of nanomaterial applications in cancer treatment.
Main Methods:
- Review of current research on nanomaterial applications in cancer immunotherapy.
- Analysis of how nanomaterials interact with the TME to facilitate drug delivery.
- Examination of different types of nanomaterials and their specific effects on immunotherapy.
Main Results:
- Nanomaterial-based systems demonstrate potential in overcoming TME-related obstacles to immunotherapy.
- These systems can deliver various agents, including cytotoxic drugs and cytokines, with reduced toxicity.
- Different nanomaterials may offer unique advantages in boosting cancer immunotherapy.
Conclusions:
- Nanomaterial-based drug delivery systems represent a promising strategy to enhance cancer immunotherapy efficacy.
- Further research focusing on biocompatibility and reduced cytotoxicity is crucial for clinical translation.
- These advanced delivery systems could lead to more effective and personalized cancer treatment options.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...